Literature DB >> 3550267

[Katacalcin--a new tumor marker in C-cell cancer of the thyroid gland].

F Raue, M Boden, S Girgis, E Rix, R Ziegler.   

Abstract

Katacalcin (KC) is situated on the C-terminal side of the procalcitonin molecule and is cleaved like calcitonin (CT) from this precursor peptide. Serum levels of KC were measured in 22 patients with C-cell carcinoma with a specific and sensitive radioimmunoassay (normal range, less than 0.1-0.15 ng/ml). Basal serum KC values in C-cell carcinoma patients were 0.32-290 ng/ml. There was a good correlation between KC and CT (r = 0.98, P less than 0.001). Serum KC, as well as CT, markedly increased after pentagastrin and calcium infusion. KC and CT were secreted in nearly equimolar amounts. During selective venous catheterization, KC and CT levels were increased in serum samples from veins draining tumor masses, which could be confirmed operatively. During the follow up, KC and CT measurements correlated well to the stage of disease. KC could be immunohistologically localized in C-cell carcinoma tissue. As a tumor marker, katacalcin is likely to be as useful as calcitonin in C-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3550267     DOI: 10.1007/BF01745480

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  A second plasma calcium-lowering peptide from the human calcitonin precursor--a re-evaluation.

Authors:  I MacIntyre; C J Hillyard; J J Reynolds; R E Das; R K Craig
Journal:  Nature       Date:  1984 Mar 1-7       Impact factor: 49.962

2.  The construction and partial characterization of plasmids containing complementary DNA sequences to human calcitonin precursor polyprotein.

Authors:  J Allison; L Hall; I MacIntyre; R K Craig
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

3.  A second plasma calcium-lowering peptide from the human calcitonin precursor.

Authors:  I MacIntyre; C J Hillyard; P K Murphy; J J Reynolds; R E Das; R K Craig
Journal:  Nature       Date:  1982-12-02       Impact factor: 49.962

4.  Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides.

Authors:  R K Craig; L Hall; M R Edbrooke; J Allison; I MacIntyre
Journal:  Nature       Date:  1982-01-28       Impact factor: 49.962

5.  [Tumor markers in C-cell cancer].

Authors:  F Raue; H Schmidt-Gayk; R Ziegler
Journal:  Dtsch Med Wochenschr       Date:  1983-02-25       Impact factor: 0.628

6.  The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma.

Authors:  P Rougier; C Calmettes; A Laplanche; J P Travagli; M Lefevre; C Parmentier; G Milhaud; M Tubiana
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

7.  Medullary thyroid carcinoma: importance of serial serum calcitonin measurement.

Authors:  A V Stepanas; N A Samaan; C S Hill; R C Hickey
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

8.  Katacalcin: a new plasma calcium-lowering hormone.

Authors:  C J Hillyard; C Myers; G Abeyasekera; J C Stevvensvenson; R K Craig; I MacIntyre
Journal:  Lancet       Date:  1983-04-16       Impact factor: 79.321

9.  Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: biochemical and immunocytochemical studies.

Authors:  F Raue; G Boller; E Rix; H Schmidt-Gayk; R Ziegler
Journal:  Klin Wochenschr       Date:  1985-03-01

10.  Immunocytochemical localisation of katacalcin, a calcium-lowering hormone cleaved from the human calcitonin precursor.

Authors:  A Ali-Rachedi; I M Varndell; P Facer; C J Hillyard; R K Craig; I MacIntyre; J M Polak
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

View more
  2 in total

1.  Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma.

Authors:  E Blind; F Raue; T Klaiber; A Zink; J Schroth; H Buhr; R Ziegler
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

2.  Presymptomatic screening for medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2A.

Authors:  A Frilling; H D Röher; B A Ponder
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.